Stem Cell Assurance, Inc. Announces the Appointment of Naiyer Imam, M.D., M.Sc., To Its Newly Established Scientific Advisory Board
JUPITER, Fla., June 20, 2011 /PRNewswire/ -- Stem Cell Assurance, Inc. (SCLZ.PK) today announced it has created a Scientific Advisory Board and has appointed Naiyer Imam, M.D., M.Sc. to serve as an advisor. Dr. Imam will assist the Company in establishing strategic relationships with leading physicians, scientists, and medical institutions as well as participating in potential clinical trials and stem cell applications.
Dr. Imam received a Medical Degree at an accelerated program from Brown University, as well as a Bachelors of Science degree in Mathematics and Computer Science. In addition, he obtained a Master of Science degree in Biostatistics at Harvard University. Dr. Imam completed his radiology training at USF in Florida and a neuroradiology fellowship at Johns Hopkins Medical Institutions in Baltimore, MD. His previous academic posting include Assistant Professor at Johns Hopkins Medical Institutions and Professor of Radiology at Virginia Tech School of Medicine. Dr. Imam is well published in the medical and radiological literature as a physician, computer scientist and businessman.
Dr. Imam is currently serving as the chairman and CEO of Advanced Medical Imaging and Teleradiology, LLC -- a new-generation teleradiology corporation that he founded in 2009. Dr. Imam is also the chairman of Gulf Advanced Imaging Corporation, a growing network of imaging centers based in Dubai, UAE. He has previously served as medical director for NightHawk Radiology Services, a publicly traded corporation, and chairman of American Teleradiology Nighthawks (ATN). He has previously served as chairman of Medical Imaging Specialists, a radiology corporation that he founded in Virginia, which served as a base for a number of imaging centers and surgical centers that Dr. Imam has either founded or developed.
Dr. Imam commented, "I am delighted to be involved with Stem Cell Assurance as a member of its Scientific Advisory Board. Stem cell science is a very exciting and evolving industry and Stem Cell Assurance is appropriately building its management and advisory team to ensure progressive strides in its research and clinical initiatives."
Mark Weinreb, Stem Cell Assurance's Chairman and Chief Executive Officer, said, "We are very pleased to have Dr. Imam, a highly regarded physician and scientist, join our Scientific Advisory Board. His expertise in medicine, science and business will prove to be highly beneficial to the Company's ongoing efforts in supporting our growth and expansion."
About Stem Cell Assurance, Inc.
Stem Cell Assurance, Inc.'s goal is to become a medical center of excellence using cell and tissue regenerative therapy protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for its future clinical procedures and outcomes and its incorporation of adult stem cell collection and storage services for future personal medical applications. The Company also operates a wholly-owned subsidiary, Stem Cellutrition, which plans to offer and sell facial creams and products.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10 filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Tel: (561) 904-6070
Fax: (561) 429-5684
SOURCE Stem Cell Assurance, Inc.